BIRC5 and breast cancer: Given that survivin/BIRC5 may be an attractive target for aggressive and resistant malignancies that lack effective therapies, we evaluated RNA expression of BIRC5 according to clinical and demographic variables in a large and diverse study population, the Carolina Breast Cancer Study (CBCS; N = 2174 cases: 1113 Black and 1061 non-Black; 1137 < 50 and 1037 ≥ 50 years of age) and compared these findings to those in the Cancer Genome Atlas (TCGA; N = 1095 cases: 183 Black and 816 non-Black; 295 < 50 and 798 ≥ 50 years of age).